Resources

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

• PDF (869.86 KB)

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

• External Link

A Phase 1B/2 Study of Selinexor in Combination with Backbone Therapies for Treatment of Relapsed/Refractory Multiple Myeloma

• PDF (1.10 MB)

Phase I Trial of the Combination of Selinexor (SEL), Liposomal Doxorubicin (DOX) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

• PDF (1.32 MB)

A Phase 2 Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM)

• PDF (1.44 MB)

A Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM)

XPO1, therapeutic … and prognostic target in sarcomas

• PDF (244.37 KB)

Therapeutic Potential of Targeting PAK Signaling

• External Link

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Children with Relapsed or Refractory Leukemia

• PDF (779.48 KB)

Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma

• External Link